Singapore, March 13, 2026 — Federal Express Corporation (FedEx), one of the world’s largest express transportation companies, has been recognized as the ‘Best Logistics & Supply Chain Management Supplier for Last Mile Implementation’ at the Asia-Pacific Biopharma Excellence Awards 2026 (ABEA 2026).
Organized by IMAPAC | BioSupply Chain Asia 2026 as part of Bio Supply Chain Asia 2026, the awards honor leaders advancing bioprocessing, logistics, supply chain management, and clinical research across the region.
Asia’s healthcare market is accelerating toward ~US$5 trillion by 2030, contributing nearly ~40% of global healthcare growth[1], while the Asia-Pacific healthcare cold chain logistics market is projected to reach ~US$42.5B by 2031[2] (up from ~US$31.9B in 2025). These shifts underscore the urgent need for high-reliability, end-to-end healthcare logistics partners capable of safeguarding increasingly complex and temperature-sensitive therapies.
“We’re honored to receive this recognition, which reflects the trust our healthcare customers place in us,” said Salil Chari, president, Asia Pacific, FedEx. “As therapies become more specialized and temperature‑sensitive, logistics demands increase significantly. FedEx meets these needs through purpose-built life sciences operations, an extensive global network, and disciplined execution, ensuring every shipment moves with reliability, visibility, and the highest standards of care.”
This award reinforces the core FedEx healthcare value proposition:
- End-to-end temperature control across deep-frozen (~–70°C), frozen (~–20°C), refrigerated (2–8°C), and controlled ambient (typically ~15–25°C) ranges.
- Purpose-built Life Science Centers in Seoul (South Korea), Singapore, Tokyo (Japan), Mumbai (India), Memphis (U.S.A), and Veldhoven (Netherlands), providing specialized handling, monitoring and intervention.
- Over 130 cold-chain facilities worldwide, maintaining temperature integrity across cross-border, multimodal networks.
- CEIV Pharma Corporate Certification at Guangzhou Baiyun International Airport (CAN) and Kansai International Airport (KIX), along with 22 FedEx facilities operating under the CEIV Pharma quality frameworks globally.
Together, these differentiators position FedEx as a mission-critical partner for the movement of biologics, vaccines, cell and gene therapies and other high-value healthcare shipments.
Held alongside the 13th Annual Biologics Manufacturing Asia on 11th March 2026 in Singapore, ABEA 2026 convened hundreds of industry leaders to spotlight innovations that enable the secure, compliant, and timely movement of lifesaving therapies. FedEx’s award highlights the company’s ability to deliver at scale, particularly where speed, precision, and temperature assurance are essential. With increasing demand for high-value therapies and expanding intra-Asia trade flows, FedEx continues to expand capabilities to ensure shipment integrity from lab to patient.
For healthcare organizations, research institutes, and manufacturers, FedEx enables confident shipment of time and temperature-critical products through its International Express network, time-critical special services (SpS), and its integrated global infrastructure. To explore more insights, visit: FedEx Business Insights.
[1] The Unmissable Asia Healthcare Opportunity | BCG
[2] Asia-Pacific Healthcare Cold Chain Logistics Market - Size, Share & Statistical Analysis